<DOC>
	<DOCNO>NCT00002442</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness 2 dosing schedule ( daily v twice daily ) lamivudine ( 3TC ) give stavudine ( d4T ) either indinavir ( IDV ) nelfinavir ( NFV ) 24 week .</brief_summary>
	<brief_title>A Study Compare Safety Effectiveness Two Dosing Schedules Lamivudine Combination With Two Other Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize 1 2 group . Group 1 receive 3TC qd plus d4T plus either IDV NFV . Group 2 receive 3TC bid plus d4T plus either IDV NFV . Patients evaluated drug tolerance , medication adherence , genotypic phenotypic resistance .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Are least 18 year old . Have HIV level 400 copies/ml least 3 month prior study entry . Have CD4 cell count least 50 cells/mm3 . Are currently take antiHIV drug regimen include 3TC plus d4T plus either IDV NFV least 6 month prior study entry . ( Note : This must first antiHIV drug regimen . ) Agree abstain sex use effective method birth control study . Exclusion Criteria Patients eligible study : Have history AIDSdefining illness certain medical condition . Are allergic study drug . Are unable take medication mouth reason . Have receive certain medication . Will need receive radiation therapy chemotherapy ( cancer Kaposi 's sarcoma ) study . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>